Status:
ACTIVE_NOT_RECRUITING
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
Lead Sponsor:
Alfasigma S.p.A.
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
An observational study to describe the effectiveness, safety, and patient-reported outcomes in patients with moderate to severe active rheumatoid arthritis (RA) receiving filgotinib in real-world sett...
Eligibility Criteria
Inclusion
- Patients aged ≥ 18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local standard of care and product label for the first time.
- Patients must be willing and able to use an electronic device to complete the study patient-reported outcome (PRO).
Exclusion
- \- Participation in any other interventional or non-interventional study without prior approval from the Medical Monitor. This does not preclude inclusion of patients enrolled to national registries.
Key Trial Info
Start Date :
May 11 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2028
Estimated Enrollment :
1304 Patients enrolled
Trial Details
Trial ID
NCT04871919
Start Date
May 11 2021
End Date
June 1 2028
Last Update
September 15 2025
Active Locations (89)
Enter a location and click search to find clinical trials sorted by distance.
1
Algemeen Stedelijk Ziekenhuis
Aalst, Belgium, 9300
2
Imelda VZW
Bonheiden, Belgium, 2820
3
AZ Sint-Jan Brugge-Oostende
Bruges, Belgium, 8000
4
Hôpital Erasme
Brussels, Belgium, 1070